Chapter 16.7
The Liver in Intracellular and Extracellular Lipidosis
Dominique P. Germain,
Dominique P. Germain
Search for more papers by this authorDominique P. Germain,
Dominique P. Germain
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this authorFirst published: 18 June 2007
References
- Brady RO Kanfer JN Shapiro D (1965) Metabolism of glucocere-brosidase II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 18, 221–225.
- Brady RO Pentchev PG Gal AE et al. (1974) Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's diseas. N Engl J Med 291, 989–993.
- Lachmann RH Wight DG Lomas DJ et al. (2000) Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. Q J Med 93, 237–244.
- Wenstrup RJ Roca-Espiau M et al. (2002) Skeletal aspects of Gaucher disease: a review Br J Radiol 75 (Suppl. 1), A2–A12.
- Maas M Hollak CE Akkerman EM et al. (2002) Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol 179, 961–965.
- Mistry PK Sirrs S Chan A et al. (2002) Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77, 91–98.
- Dawson A Elias DJ Rubenson D et al. (1996) Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 125, 901–904.
- Beutler E Demina A Laubscher K et al. (1995) The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 21, 86–108.
- Maaswinkel-Mooij P Hollak C van Eysden-Plaisier M et al. (2000) The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 23, 77–82.
- Sidransky E Sherer DM Ginns EI (1992) Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr Res 32, 494–498.
- Brady RO Barton NW Grabowski GA (1993) The role of neurogenetics in Gaucher disease. Arch Neurol 50, 1212–1224.
- Erikson A (1986) Gaucher disease: Norrbottnian type 3. Neuropediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand 326, 1–42.
- George R McMahon J Lytle B et al. (2001) Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation. Clin Genet 59, 360–363.
- Hollak CEM van Weely S van Oers MHJ Aerts JMFG (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher diseas. J Clin Invest 93, 1288–1292.
- Boot RG Verhoek M De Fost M et al. (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103, 33–39.
- Grabowski GA (1997) Gaucher disease: gene frequencies and genotype/phenotype correlation. Genet Test 1, 5–12.
- Germain DP Puech JP Caillaud C et al. (1998) Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher diseas. Am J Hum Genet 63, 415–427.
- NIH Technology Assessment Panel on Gaucher Disease (1996) Gaucher disease. Current issues in diagnosis and treatment. JAMA 275, 548–553.
- Lachmann RH Grant IR Halsall D Cox TM (2004) Twin pairs showing discordance of phenotype in adult Gaucher's diseas. Q J Med 97, 199–204.
- Barton NW Brady RO Dambrosia JM et al. (1991) Replacement therapy for inherited enzyme deficiency — macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324, 1464–1470.
- Wenstrup RJ Bailey L Grabowski GA et al. (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therap. Blood 104, 1253–1257.
- Weinreb NJ Charrow J Andersson HC et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registr. Am J Med 113, 112–119.
- Grabowski GA Hopkin RJ (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospect. Annu Rev Genomics Hum Genet 4, 403–436.
- Perel Y Bioulac-Sage P Chateil JF et al. (2002) Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therap. Pediatrics 109, 1170–1173.
- Damiano AM Pastores GM Ware JE Jr (1998) The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective stud. Qual Life Res 7, 373–386.
- Altarescu G Schiffmann R Parker CC et al. (2000) Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher diseas. Blood Cells Mol Dis 26, 285–290.
- Cox TM Aerts JM Andria G et al. (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26, 513–526.
- Brady RO Murray GJ Oliver KL et al. (1997) Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 100, e11–e14.
- Germain DP Kaneski CR Brady RO (2001) Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to algluceras. Mutat Res 483, 89–94.
- Starzl TE Demetris AJ Trucco M et al. (1993) Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's diseas. N Engl J Med 328, 745–749.
- Carlson DE Busuttil RW Giudici TA Barranger JA (1990) Orthotopic liver transplantation in the treatment of complications of type 1 Gaucher diseas. Transplantation 49, 1192–1194.
- Cox T Lachmann R Hollak C et al. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesi. Lancet 355, 1481–1485.
- Heitner R Elstein D Aerts J et al. (2002) Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher diseas. Blood Cells Mol Dis 28, 127–133.
- Sawkar AR Adamski-Werner SL Cheng WC et al. (2005) Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profile. Chem Biol 12, 1235–1244.
- Vellodi A Bembi B de Villemeur TB et al. (2001) Management of neuronopathic Gaucher disease: a European consensu. J Inherit Metab Dis 24, 319–327.
- Kohn DB (2001) Gene therapy for genetic haematological disorders and immunodeficiencies. J Intern Med 249, 379–390.
- Kim EY Hong YB Lai Z et al. (2005) Long-term expression of the human glucocerebrosidase gen. in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector J Gene Med 7, 878–887.
- Lee KO Luu N Kaneski CR et al. (2005) Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domai. Biochem Biophys Res Commun 337, 701–707.
- McGovern MM Aron A Brodie SE et al. (2006) Natural history of type A Niemann-Pick disease: possible endpoints for therapeutic trial. Neurology 66, 228–232.
- Wasserstein MP Desnick RJ Schuchman EH et al. (2004) The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal stud. Pediatrics 114, e672–e677.
- Pentchev PG (2004) Niemann-Pick C research from mouse to gen. Biochim Biophys Acta 1685, 3–7.
- Vanier MT Millat G (2003) Niemann-Pick disease type. Clin Genet 64, 269–281.
- Patterson MC Platt F (2004) Therapy of Niemann-Pick disease, type. Biochim Biophys Acta 1685, 77–82.
- Assmann G Seedorf U (2001) Acid lipase deficiency: Wolman disease and cholesteryl ester storage deficiency. In: CR Scriver, WS Sly, A. Barton Childs et al.(eds) The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, pp. 3551–3572.
- Wetterau JR Aggerbeck LP Bouma ME et al. (1992) Absence of microsomal triglyceride transfer protein in individuals with abeta-lipoproteinemi. Science 258, 999–1001.
- Kane JP Havel R (2001) Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: CR Scriver, WS Sly, AL Barton Childs et al.(eds) The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill pp. 2717–2752.
- Schonfeld G (2003) Familial hypobetalipoproteinemia: a revie. J Lipid Res 44, 878–883.
- Brunzell JD Deeb SS (2001) Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In: CR Scriver, WS Sly, A Barton Childs. et al.(eds) The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, pp. 2789–2816.
- Goldstein JL Hobbs HH Brown MS (2001) Familial hypercholesterolemia. In: CR Scriver, WS Sly, A. Barton Childs et al.(eds) The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, pp. 2863–2913.
